{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:34:29Z","timestamp":1783398869804,"version":"3.54.6"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002349","name":"Egyptian Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ejmech.2024.116255","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T11:19:29Z","timestamp":1708168769000},"page":"116255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Novel sulfonamide-indolinone hybrids targeting mitochondrial respiration of breast cancer cells"],"prefix":"10.1016","volume":"268","author":[{"given":"Sama W.A.","family":"Helmy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal Kamal","family":"Abdel-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2770-6439","authenticated-orcid":false,"given":"Eman M.E.","family":"Dokla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek E.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Hatem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engy A.","family":"Abdel Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Sharaky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai I.","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman Z.","family":"Elrazaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabah A.T.","family":"Serya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maged","family":"Henary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh S.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalal A.","family":"Abou El Ella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116255_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e21344","article-title":"Review: predictive approaches to breast cancer risk","author":"Huang","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.ejmech.2024.116255_bib2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3322\/caac.21754","article-title":"Breast cancer statistics, 2022, CA","volume":"72","author":"Giaquinto","year":"2022","journal-title":"A Cancer Journal for Clinicians"},{"key":"10.1016\/j.ejmech.2024.116255_bib3","unstructured":"Cancer of the Breast (Female) - Cancer Stat Facts, SEER (n.d.). https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html (accessed November 20, 2023)."},{"key":"10.1016\/j.ejmech.2024.116255_bib4","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer\u2014epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014an updated review","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.116255_bib5","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3389\/fonc.2020.00864","article-title":"Breast cancer survivorship, quality of life, and late toxicities","volume":"10","author":"Nardin","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2024.116255_bib6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s12955-020-01591-x","article-title":"Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018","volume":"18","author":"Mokhtari-Hessari","year":"2020","journal-title":"Health Qual. Life Outcome"},{"key":"10.1016\/j.ejmech.2024.116255_bib7","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.3390\/jcm11237239","article-title":"Long-term effects of breast cancer therapy and care: calm after the storm?","volume":"11","author":"Tommasi","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2024.116255_bib8","article-title":"Targeting protein kinases benefits cancer immunotherapy","volume":"1877","author":"Zhang","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejmech.2024.116255_bib9","doi-asserted-by":"crossref","first-page":"6869","DOI":"10.1158\/1078-0432.CCR-06-1405","article-title":"Aurora kinases: new targets for cancer therapy","volume":"12","author":"Carvajal","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116255_bib10","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.biocel.2005.02.021","article-title":"Aurora kinases","volume":"37","author":"Bolanos-Garcia","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejmech.2024.116255_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.critrevonc.2009.03.009","article-title":"Aurora kinase inhibitors","volume":"73","author":"Kitzen","year":"2010","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2024.116255_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5507\/bp.2008.004","article-title":"Aurora kinases: structure, functions and their association with cancer","volume":"152","author":"Kollareddy","year":"2008","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1016\/j.ejmech.2024.116255_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ctrv.2007.09.005","article-title":"Aurora kinases as targets for cancer therapy","volume":"34","author":"Mountzios","year":"2008","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2024.116255_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.136178","article-title":"Selective targeting of Aurora kinase B over A: uncovering the structural basis for inhibitor specificity through molecular dynamics simulations","volume":"1292","author":"Zhao","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2024.116255_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113495","article-title":"Aurora kinase inhibitors as potential anticancer agents: recent advances","volume":"221","author":"Pradhan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116255_bib16","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1016\/j.bmcl.2009.04.136","article-title":"The discovery of the potent aurora inhibitor MK-0457 (VX-680)","volume":"19","author":"Bebbington","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116255_bib17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1083\/jcb.200208091","article-title":"Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad 2, and Cenp-E to kinetochores","volume":"161","author":"Ditchfield","year":"2003","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2024.116255_bib18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1083\/jcb.200208092","article-title":"The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore\u2013microtubule attachment and in maintaining the spindle assembly checkpoint","volume":"161","author":"Hauf","year":"2003","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2024.116255_bib19","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1021\/jm061335f","article-title":"Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase","volume":"50","author":"Mortlock","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116255_bib20","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.chembiol.2008.04.013","article-title":"Molecular basis of drug resistance in aurora kinases","volume":"15","author":"Girdler","year":"2008","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116255_bib21","doi-asserted-by":"crossref","first-page":"7841","DOI":"10.1021\/jm3008954","article-title":"Crystal structure of human aurora B in complex with INCENP and VX-680","volume":"55","author":"Elkins","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116255_bib22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.molcel.2005.03.031","article-title":"Mechanism of aurora B activation by INCENP and inhibition by hesperadin","volume":"18","author":"Sessa","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2024.116255_bib23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1107\/S2053230X14002118","article-title":"Structure of Aurora B\u2013INCENP in complex with barasertib reveals a potential transinhibitory mechanism","volume":"70","author":"Sessa","year":"2014","journal-title":"Acta Crystallogr. F"},{"key":"10.1016\/j.ejmech.2024.116255_bib24","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ebiom.2015.05.022","article-title":"Is cancer a genetic disease or a metabolic disease?","volume":"2","author":"Wishart","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejmech.2024.116255_bib25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/his.13334","article-title":"Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations","volume":"72","author":"El Ansari","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.ejmech.2024.116255_bib26","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2174\/1568009617666170330150458","article-title":"Potential therapeutic targets in energy metabolism pathways of breast cancer","volume":"17","author":"Islam","year":"2017","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejmech.2024.116255_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101534","article-title":"Energy metabolism pathways in breast cancer progression: the reprogramming, crosstalk, and potential therapeutic targets","volume":"26","author":"Zheng","year":"2022","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ejmech.2024.116255_bib28","article-title":"The Warburg effect on radioresistance: survival beyond growth","volume":"1878","author":"Kang","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejmech.2024.116255_bib29","first-page":"5789","article-title":"Relationship between metabolic reprogramming and mitochondrial activity in cancer cells. Understanding the anticancer effect of metformin and its clinical implications","volume":"35","author":"Cazzaniga","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2024.116255_bib30","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/ars.2007.1957","article-title":"Redox regulation of cell survival","volume":"10","author":"Trachootham","year":"2008","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.ejmech.2024.116255_bib31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.trecan.2018.11.003","article-title":"Gluconeogenesis in cancer: function and regulation of PEPCK, FBPase, and G6Pase","volume":"5","author":"Wang","year":"2019","journal-title":"Trends in Cancer"},{"key":"10.1016\/j.ejmech.2024.116255_bib32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mito.2012.06.007","article-title":"ROS, autophagy, mitochondria and cancer: ras, the hidden master?","volume":"13","author":"Bellot","year":"2013","journal-title":"Mitochondrion"},{"key":"10.1016\/j.ejmech.2024.116255_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bj.2017.12.001","article-title":"Structure and mechanism of mitochondrial electron transport chain","volume":"41","author":"Guo","year":"2018","journal-title":"Biomed. J."},{"key":"10.1016\/j.ejmech.2024.116255_bib34","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.3390\/ijms24054954","article-title":"Targeting mitochondrial metabolic reprogramming as a potential approach for cancer therapy","volume":"24","author":"Zhang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116255_bib35","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.semcancer.2022.02.002","article-title":"Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications","volume":"86","author":"Greene","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2024.116255_bib36","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1158\/0008-5472.CAN-20-3242","article-title":"Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple-negative breast cancer","volume":"81","author":"Evans","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116255_bib37","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1038\/s41467-023-40022-5","article-title":"Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers","volume":"14","author":"El-Botty","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116255_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.779169","article-title":"SIPA1 enhances aerobic glycolysis through HIF-2\u03b1 pathway to promote breast cancer metastasis","volume":"9","author":"Yao","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2024.116255_bib39","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.02242","article-title":"Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis","volume":"3","author":"Wheaton","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.ejmech.2024.116255_bib40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bbrc.2018.02.063","article-title":"Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress","volume":"497","author":"Wang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2024.116255_bib41","first-page":"428","article-title":"Fenofibrate-induced mitochondrial dysfunction and metabolic reprogramming reversal: the anti-tumor effects in gastric carcinoma cells mediated by the PPAR pathway","volume":"12","author":"Chen","year":"2020","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.ejmech.2024.116255_bib42","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.semcancer.2022.02.002","article-title":"Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications","volume":"86","author":"Greene","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2024.116255_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115219","article-title":"Recent advances of mitochondrial complex I inhibitors for cancer therapy: current status and future perspectives","volume":"251","author":"Zhou","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116255_bib44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/cells8020089","article-title":"Metabolic reprogramming in breast cancer and its therapeutic implications","volume":"8","author":"Gandhi","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2024.116255_bib45","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.3390\/cancers15133390","article-title":"Role of glucose metabolic reprogramming in breast cancer progression and drug resistance","volume":"15","author":"Lei","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.116255_bib46","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/11318860-000000000-00000","article-title":"Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies","volume":"23","author":"Papaetis","year":"2009","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejmech.2024.116255_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113334","article-title":"Structural insights of oxindole based kinase inhibitors as anticancer agents: recent advances","volume":"216","author":"Dhokne","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116255_bib48","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1158\/1535-7163.MCT-14-0832","article-title":"The novel ATP-competitive MEK\/aurora kinase inhibitor BI-847325 overcomes acquired BRAF inhibitor resistance through suppression of mcl-1 and MEK expression","volume":"14","author":"Phadke","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116255_bib49","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1158\/0008-5472.CAN-05-0574","article-title":"Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling","volume":"65","author":"Godl","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116255_bib50","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.bmcl.2005.09.064","article-title":"Synthesis and biological evaluation of 3-ethylidene-1,3-dihydro-indol-2-ones as novel checkpoint 1 inhibitors","volume":"16","author":"Lin","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116255_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105451","article-title":"Indolin-2-one derivatives as selective Aurora B kinase inhibitors targeting breast cancer","volume":"117","author":"Dokla","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.116255_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0033583508004745","article-title":"Protein kinase inhibitors: contributions from structure to clinical compounds","volume":"42","author":"Johnson","year":"2009","journal-title":"Q. Rev. Biophys."},{"key":"10.1016\/j.ejmech.2024.116255_bib53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/B978-0-12-397918-6.00004-5","article-title":"Targeting protein kinases with selective and semi-promiscuous covalent inhibitors","volume":"548","author":"Miller","year":"2014","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ejmech.2024.116255_bib54","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2024.116255_bib55","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2024.116255_bib56","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2174\/1568026617666161116143440","article-title":"Bioinformatics and drug discovery","volume":"17","author":"Xia","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116255_bib57","series-title":"CADD and Informatics in Drug Discovery","first-page":"1","article-title":"Role of bioinformatics in drug design and discovery","author":"Patel","year":"2023"},{"key":"10.1016\/j.ejmech.2024.116255_bib58","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","article-title":"The NCI60 human tumour cell line anticancer drug screen","volume":"6","author":"Shoemaker","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.116255_bib59","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1471-2164-7-166","article-title":"Comparative analysis and integrative classification of NCI60 cell lines and primary tumors using gene expression profiling data","volume":"7","author":"Wang","year":"2006","journal-title":"BMC Genom."},{"key":"10.1016\/j.ejmech.2024.116255_bib60","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1186\/1471-2105-12-S1-S36","article-title":"Integrated metabolome and transcriptome analysis of the NCI60 dataset","volume":"12","author":"Su","year":"2011","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.ejmech.2024.116255_bib61","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.celrep.2013.07.018","article-title":"Global proteome analysis of the NCI-60 cell line panel","volume":"4","author":"Gholami","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2024.116255_bib62","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/1878-0261.12849","article-title":"Molecular genomic features associated with in vitro response of the NCI-60 cancer cell line panel to natural products","volume":"15","author":"Krushkal","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2024.116255_bib63","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/1535-7163.MCT-23-0267","article-title":"Targeted investigational oncology agents in the NCI-60: a phenotypic systems\u2013based resource","volume":"22","author":"Morris","year":"2023","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116255_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112316","article-title":"Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors","volume":"197","author":"Matheson","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116255_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111607","article-title":"1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC","volume":"182","author":"Dokla","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116255_bib66","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1021\/jm0204183","volume":"46","author":"Sun","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116255_bib67","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejmech.2016.12.038","article-title":"Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase 3 (FLT3)","volume":"127","author":"Ma","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116255_bib68","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejmech.2014.05.051","article-title":"Synthesis and in vivo SAR study of indolin-2-one-based multi-targeted inhibitors as potential anticancer agents","volume":"82","author":"Zhang","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116255_bib69","doi-asserted-by":"crossref","first-page":"R357","DOI":"10.1530\/ERC-14-0232","article-title":"The kinome associated with estrogen receptor-positive status in human breast cancer","volume":"21","author":"Bruce","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ejmech.2024.116255_bib70","doi-asserted-by":"crossref","first-page":"8746","DOI":"10.1038\/ncomms9746","article-title":"IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel","volume":"6","author":"Wee","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116255_bib71","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.3390\/ijms18122543","article-title":"Protein kinase targets in breast cancer","volume":"18","author":"Garc\u00eda-Aranda","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116255_bib72","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12943-018-0797-x","article-title":"Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges","volume":"17","author":"Butti","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2024.116255_bib73","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1016\/j.celrep.2018.11.103","article-title":"Dual mechanisms of LYN kinase dysregulation drive aggressive behavior in breast cancer cells","volume":"25","author":"Tornillo","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2024.116255_bib74","article-title":"The emerging role of c-met in carcinogenesis and clinical implications as a possible therapeutic target","volume":"2022","author":"Faiella","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejmech.2024.116255_bib75","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/s41416-020-01040-y","article-title":"OXPHOS-dependent metabolic reprogramming prompts metastatic potential of breast cancer cells under osteogenic differentiation","volume":"123","author":"Hu","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2024.116255_bib76","doi-asserted-by":"crossref","first-page":"47691","DOI":"10.18632\/oncotarget.17868","article-title":"Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer","volume":"8","author":"Qian","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2024.116255_bib77","article-title":"Six glycolysis-related genes as prognostic risk markers can predict the prognosis of patients with head and neck squamous cell carcinoma","volume":"2021","author":"Chen","year":"2021","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejmech.2024.116255_bib78","doi-asserted-by":"crossref","first-page":"322","DOI":"10.52586\/4946","article-title":"PLOD1 promotes cell growth and aerobic glycolysis by regulating the SOX9\/PI3K\/Akt\/mTOR signaling pathway in gastric cancer","volume":"26","author":"Zhang","year":"2021","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejmech.2024.116255_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102240","article-title":"Secretory pathway Ca2+-ATPase SPCA2 regulates mitochondrial respiration and DNA damage response through store-independent calcium entry","volume":"50","author":"Makena","year":"2022","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejmech.2024.116255_bib80","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1073\/pnas.1001006107","article-title":"Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function","volume":"107","author":"Hu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2024.116255_bib81","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1074\/jbc.RA118.004365","article-title":"S100A4 alters metabolism and promotes invasion of lung cancer cells by up-regulating mitochondrial complex i protein NDUFS2","volume":"294","author":"Liu","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116255_bib82","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/ng.3984","article-title":"Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells","volume":"49","author":"Meyers","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2024.116255_bib83","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.18632\/oncotarget.27743","article-title":"Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis","volume":"11","author":"Kim","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2024.116255_bib84","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50141-z","article-title":"Role of mitochondria in rescuing glycolytically inhibited subpopulation of triple negative but not hormone-responsive breast cancer cells","volume":"9","author":"Reda","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2024.116255_bib85","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41467-019-13668-3","article-title":"Mitochondrial TCA cycle metabolites control physiology and disease","volume":"11","author":"Mart\u00ednez-Reyes","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116255_bib86","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with the tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.116255_bib87","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.expneurol.2016.06.004","article-title":"The tyrosine kinase inhibitor, sunitinib malate, induces cognitive impairment in vivo via dysregulating VEGFR signaling, apoptotic and autophagic machineries","volume":"283","author":"Abdel-Aziz","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejmech.2024.116255_bib88","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3389\/fphar.2017.00718","article-title":"From resistance to sensitivity: insights and implications of biphasic modulation of autophagy by sunitinib","volume":"8","author":"Abdel-Aziz","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116255_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115709","article-title":"Advances in acute myeloid leukemia differentiation therapy: a critical review","volume":"215","author":"Abdel-Aziz","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116255_bib90","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1535-7163.MCT-10-0106","article-title":"Analysis of FDA-approved anti-cancer agents in the NCI60 panel of human tumor cell lines","volume":"9","author":"Holbeck","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116255_bib91","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/jcb.30238","article-title":"Preclinical activity of fluvastatin-loaded self-nanoemulsifying delivery system against breast cancer models: emphasis on apoptosis","volume":"123","author":"Elimam","year":"2022","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejmech.2024.116255_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115316","article-title":"Discovery of EMD37, a 1,2,4-oxadiazole derivative, as a novel endoplasmic reticulum stress inducer with potent anticancer activity","volume":"206","author":"Abdel-Aziz","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116255_bib93","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.ejmech.2024.116255_bib94","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/bioinformatics\/bty895","article-title":"Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences","volume":"35","author":"Zhu","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejmech.2024.116255_bib95","first-page":"91","article-title":"An introduction to survival statistics: kaplan-meier analysis","volume":"7","author":"Dudley","year":"2016","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.ejmech.2024.116255_bib96","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s11357-023-00742-4","article-title":"Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer","volume":"45","author":"Gyorffy","year":"2023","journal-title":"Geroscience"},{"key":"10.1016\/j.ejmech.2024.116255_bib97","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jare.2021.01.006","article-title":"Sleep\/wake calcium dynamics, respiratory function, and ROS production in cardiac mitochondria","volume":"31","author":"Abdel-Rahman","year":"2021","journal-title":"J. Adv. Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424001351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424001351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:06:37Z","timestamp":1759331197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424001351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":97,"alternative-id":["S0223523424001351"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116255","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel sulfonamide-indolinone hybrids targeting mitochondrial respiration of breast cancer cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116255"}}